#1 Clinical Trials Search in Europe

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

3 1 1 1

What is this study about?

This clinical trial is focused on studying the effectiveness and safety of a medication called Ocrelizumab in patients with Multiple Sclerosis (MS). Multiple Sclerosis is a condition that affects the brain and spinal cord, leading to a range of symptoms such as problems with vision, arm or leg movement, sensation, or balance. The study involves patients who have previously participated in a related clinical trial sponsored by the pharmaceutical company Roche.

The purpose of this study is to evaluate how well Ocrelizumab works in managing MS symptoms and its safety over time. Participants will receive the medication through an intravenous infusion, which means it is administered directly into the bloodstream. The study will monitor various aspects of the disease, including any changes in disability levels, the occurrence of relapses, and overall disease activity. Additionally, the study will use MRI scans to observe changes in the brain that are associated with MS.

Throughout the study, participants will be regularly assessed to track their progress and any side effects they may experience. The study aims to provide valuable information on the long-term use of Ocrelizumab in treating MS, helping to improve understanding of its benefits and risks for patients living with this condition.

1 initial visit and assessment

Upon joining the study, an initial visit is conducted to assess eligibility. This includes a review of medical history and current health status.

A series of tests and evaluations are performed to establish a baseline for the study. These may include physical examinations, neurological assessments, and laboratory tests.

2 treatment initiation

The treatment phase begins with the administration of methylprednisolone 500 mg as a solution for injection or infusion. This is given intravenously to prepare the body for the main treatment.

Following this, diphenhydramine hydrochloride 50 mg tablets are taken orally to help manage potential allergic reactions.

3 ocrelizumab infusion

The main treatment involves the infusion of ocrelizumab 300 mg. This is administered as a solution for infusion through a vein.

The infusion process is monitored closely to ensure safety and manage any immediate side effects.

4 supportive medication

To manage any discomfort or fever, paracetamol 1000 mg is taken orally as needed.

This medication helps in reducing fever and alleviating pain that may occur during the treatment.

5 follow-up visits

Regular follow-up visits are scheduled to monitor progress and assess the effectiveness of the treatment.

These visits include physical examinations, neurological assessments, and possibly additional laboratory tests to track changes in health status.

6 ongoing monitoring

Throughout the study, continuous monitoring is conducted to evaluate the impact of the treatment on multiple sclerosis symptoms.

This includes tracking any changes in disability progression, relapse rates, and overall quality of life.

7 final assessment

At the end of the study period, a final assessment is performed to determine the overall effectiveness and safety of the treatment.

This includes a comprehensive review of all collected data and a final evaluation of health status.

Who Can Join the Study?

  • The patient must be able to follow the study rules, as judged by the study doctor.
  • The patient must be eligible to continue into the MN39158/LIBERTO study. This includes women who were pregnant during earlier studies and are still being monitored for safety, based on the study doctor’s decision after assessing the risks and benefits of continuing treatment with ocrelizumab (a medication used to treat MS).
  • The patient must meet the criteria to receive more treatment with ocrelizumab.
  • If a patient became pregnant by chance between the last visit of the previous study and the start of this study, confirmed by pregnancy tests, they will enter a safety follow-up immediately and restart treatment after giving birth and finishing breastfeeding, according to the re-treatment criteria.
  • Women who can become pregnant must agree to either not have sexual intercourse or use an acceptable birth control method during the treatment period and for at least 6 months or longer after the last dose of ocrelizumab, as stated in the local guidelines for the medication.

Who Cannot Join the Study?

  • Patients who have not been previously enrolled in a Roche sponsored phase IIIb/IV-trial for multiple sclerosis.
  • Patients with any other significant health condition that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who are unable to follow the study procedures or attend the required visits.
  • Patients who have a history of severe allergic reactions to medications.
  • Patients who are currently participating in another clinical trial.
  • Patients with a history of drug or alcohol abuse.
  • Patients who have received any live vaccines within the last 4 weeks.
  • Patients with active infections that require treatment.
  • Patients with a history of cancer, except for certain types of skin cancer.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Zuyderland Medisch Centrum Stichting Geleen The Netherlands
Centre Hospitalier Universitaire De Bordeaux Bordeaux France
Centre Hospitalier Universitaire De Lille Lille France
CHU Grenoble Alpes La Tronche France
Policlinico “Tor Vergata”, Università degli Studi di Roma TOR VERGATA Rome Italy

Other Sites

Site Name City Country Status
KBC Zagreb Zagreb Croatia
Centre Hospitalier Universitaire Rouen Rouen France
Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania Catania Italy
MHAT National Heart Hospital EAD Sofia Bulgaria
Centre Hospitalier Universitaire De Nimes Nimes France
Azienda Ospedaliero-Universitaria Sant Andre Rome Italy
CHU Gabriel-Montpied Clermont Ferrand France
Centre hospitalier universitaire de Liege Liege Belgium
Groene Hart Ziekenhuis Gouda The Netherlands
Jeroen Bosch Ziekenhuis Stichting s-Hertogenbosch The Netherlands
Helse Stavanger HF Stavanger Norway
University Hospital Bratislava Bratislava Slovakia
UNIVERZITETNI KLINICNI CENTER MARIBOR Maribor Slovenia
Fakultna Nemocnica Trnava Trnava Slovakia
Hospital Beatriz Angelo Loures Portugal
CCAB Centro Clinico Academico Braga Associacao Braga Portugal
Region Stockholm – SLSO Stockholm Sweden
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego Warsaw Poland
Copernicus Podmiot Leczniczy Sp. z o.o. Gdansk Poland
Noorderhart Pelt Belgium
Centre Hospitalier General Gonesse France
HIA Sainte Anne Toulon France
Multiprofile Hospital For Active Treatment In Neurology And Psychiatry St. Naum EAD Sofia Bulgaria
Az St-Jan Brugge-Oostende A.V. Brugge Belgium
Instytut Psychiatrii I Neurologii Warsaw Poland
Aalborg University Hospital Aalborg Denmark
Centre Hospitalier Universitaire De Nantes Nantes France
Centre Hospitalier Universitaire De Nice Nice France
University Medical Center Ljubljana Ljubljana Slovenia
Centre hospitalier universitaire de Tivoli Institut medical des Mutualites socialistes La Louviere Belgium
Jahn Ferenc Del-Pesti Korhaz Es Rendelointezet Budapest Hungary
Neurocentrum Bydgoszcz Sp. z o.o. Bydgoszcz Poland
Rigshospitalet Copenhagen Denmark
Centro Hospitalar Universitario De Santo Antonio E.P.E. Porto Portugal
Centre Hospitalier Lyon Sud Pierre Benite France
Queen Silvia Childrens Hospital – Sahlgrenska University Hospital – Vaestra Goetalandsregionen Gothenburg Sweden
Centre Hospitalier Intercommunal De Poissy Saint Germain St Germain En Laye France
Care Clinic Sp. z o.o. Katowice Poland
Vwqrkujh Dcyahaowayqhe Klkskja Esztergom Hungary
Mtkllrabpfv Ctupulk Ddsqwuegzcctt Mqndekh Sih z ovmi Cracow Poland
Cuaiqxw Ncdrpqdqwg Kyevickpq Sghzow Lodz Poland
Agxwfvtpl Uoe Amsterdam The Netherlands
Bhiwxfkn Upfpojdgml Hlxoamzy Cftuof Besançon France
Aviugu Uxrqjwwugg Hcqvqojw Aarhus Denmark
Crxb Dv Nlcti Vandoeuvre Les Nancy France
Rlcene Vqmjvhjwo Karlstad Sweden
Uewmiqinha Ok Arzdhou Edegem Belgium
Itjynyxaqbso Pziftdch Lnztgnoz Pmfbd dc hawe nl mdnk Klwfnx Rfraxk Lublin Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
27.07.2018
Bulgaria Bulgaria
Not recruiting
27.07.2018
Croatia Croatia
Not recruiting
27.07.2018
Denmark Denmark
Not recruiting
27.07.2018
France France
Not recruiting
27.07.2018
Hungary Hungary
Not recruiting
27.07.2018
Italy Italy
Not recruiting
27.07.2018
Norway Norway
Not recruiting
27.07.2018
Poland Poland
Not recruiting
27.07.2018
Portugal Portugal
Not recruiting
27.07.2018
Slovakia Slovakia
Not recruiting
27.07.2018
Slovenia Slovenia
Not recruiting
27.07.2018
Sweden Sweden
Not recruiting
27.07.2018
The Netherlands The Netherlands
Not recruiting
27.07.2018

Trial locations

Investigated drugs:

Ocrelizumab is a medication used in the treatment of multiple sclerosis (MS), a condition where the immune system mistakenly attacks the protective covering of nerves. This medication works by targeting and reducing certain immune cells in the body that are believed to play a role in the damage caused by MS. By doing so, it helps to slow down the progression of the disease and reduce the frequency of relapses, which are periods when symptoms get worse. In this clinical trial, the effectiveness and safety of ocrelizumab are being evaluated in patients who have already participated in a previous study involving this medication.

Investigated diseases:

Multiple sclerosis (MS) – Multiple sclerosis is a chronic disease that affects the central nervous system, particularly the brain and spinal cord. It is characterized by the immune system attacking the protective sheath (myelin) that covers nerve fibers, leading to communication problems between the brain and the rest of the body. As the disease progresses, it can cause permanent damage or deterioration of the nerves themselves. Symptoms vary widely and can include fatigue, difficulty walking, numbness or tingling, muscle weakness, and problems with coordination and balance. The progression of MS can be unpredictable, with periods of new symptoms or relapses that can last for days or months, followed by periods of remission. Over time, some people with MS may experience a gradual worsening of symptoms and disability.

Trial ID:
2023-506543-41-00
Protocol code:
MN39158
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A study to compare the effectiveness and safety of subcutaneous frexalimab versus intravenous frexalimab in adults with multiple sclerosis

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy Spain

  • A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

    Recruiting

    2 1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain